Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial-Reference-Cited by-同舟云学术

Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial

Published:2020-07-14 Issue:19 Volume:26 Page:5140-5152
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Uppaluri Ravindra,Campbell Katie M.^ORCID,Egloff Ann Marie,Zolkind Paul,Skidmore Zachary L.^ORCID,Nussenbaum Brian^ORCID,Paniello Randal C.^ORCID,Rich Jason T.,Jackson Ryan,Pipkorn Patrik^ORCID,Michel Loren S.,Ley Jessica,Oppelt Peter,Dunn Gavin P.,Barnell Erica K.^ORCID,Spies Nicholas C.,Lin Tianxiang,Li Tiantian,Mulder David T.,Hanna Youstina,Cirlan Iulia^ORCID,Pugh Trevor J.^ORCID,Mudianto Tenny,Riley Rachel,Zhou Liye,Jo Vickie Y.,Stachler Matthew D.,Hanna Glenn J.,Kass Jason,Haddad Robert,Schoenfeld Jonathan D.^ORCID,Gjini Evisa^ORCID,Lako Ana,Thorstad Wade,Gay Hiram A.,Daly Mackenzie,Rodig Scott J.,Hagemann Ian S.^ORCID,Kallogjeri Dorina,Piccirillo Jay F.^ORCID,Chernock Rebecca D.,Griffith Malachi^ORCID,Griffith Obi L.^ORCID,Adkins Douglas R.

Funder

NCI

NIHNHGRINHGRI

NCINIHNIH

NIHNIDCRNIDCR

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 167 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Economic Evaluation of Neoadjuvant Versus Adjuvant Chemotherapy in Cancer Treatment: A Systematic Review and Meta-Analysis;Value in Health Regional Issues;2024-05

2. Tumor-specific T cells in head and neck cancer have rescuable functionality and can be identified through single-cell co-culture;Translational Oncology;2024-04

3. Translational research in head and neck cancer: Molecular and immunological updates;Auris Nasus Larynx;2024-04

4. Immunotherapy for head and neck squamous cell carcinoma: current status and perspectives;Immunotherapy;2024-02

5. Depletion of effector regulatory T cells drives major response to induction dual immune checkpoint blockade;2024-01-04